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Abstract The synaptotagmin gene family currently includes
12 members. Analysis of the three known genomic synaptotag-
min sequences reveals conserved exon-intron patterns which
delineate the synaptotagmin structural domains. We used
expressed sequence tag, reverse transcription PCR and RNAse
protection assay analysis of synaptotagmin messenger RNAs to
demonstrate the occurrence of alternative splicing events
involving a number of exons. Exon-skipped messages where
transmembrane sequences have been removed or altered were
found to be abundantly expressed by synaptotagmins 1, 4, 6 and
7. Although the expression of most synaptotagmins predominates
in neural tissue, we find that by contrast, synaptotagmin 6 is
more abundant in thymus.
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1. Introduction
Synaptotagmin genes are expressed mainly in neural tissue
and share a common domain structure, the de¢ning elements
of which are a N-terminal transmembrane sequence and two
C-terminal C2 domains [1,2]. A great deal is known about the
structure and function of synaptotagmin 1. Studies in vitro
and in vivo such as biochemistry, microinjections and gene
transfections with wild-type and mutant sequences [3^7], to-
gether with the solution of crystal and NMR structures of the
C2 domain [8^10] and the production of knockout mice [11],
clearly establish synaptotagmin 1 as a crucial component of
synaptic vesicles, responsible for the fast component of neuro-
transmitter release. It binds calcium, possibly acting as a cal-
cium sensor, as well as to a number of other proteins and
lipids [12^22].
Much less is known about the other 11 members of the
synaptotagmin family, but biochemical experiments with their
C2 domains reveal that the di¡erent sequences have di¡erent
a⁄nities for their various binding partners [23^29]. In situ
hybridisation studies show that the di¡erent genes have dis-
tinct but overlapping expression patterns [30^36], with some
being rapidly induced by seizures [37,38], whereas another is
induced by thyroid hormone [39]. Some synaptotagmins have
been found to play a role in calcium-regulated vesicle exocy-
tosis in peripheral tissues, for example catecholamine secretion
from chroma⁄n cells, pancreatic insulin secretion and mast
cell lysosome exocytosis [40^43]. It seems unlikely, however,
that all synaptotagmins are functionally equivalent to synap-
totagmin 1, with an integral vesicle location and a role in
calcium-regulated exocytosis. Isolated synaptotagmin C2 do-
mains can bind to membranes and lipids with or without
calcium [44^46] and recent work shows that in brain, synap-
totagmins 3 and 6 are clustered mainly at sites on the cyto-
plasmic plasma membrane rather than on synaptic vesicles
[47]. It is thus becoming apparent that the synaptotagmin
family encompasses a functional diversity which is not re-
stricted to the calcium regulation of synaptic vesicle exocyto-
sis. Here, we show that tissue-speci¢c expression and alterna-
tive splicing further add to the potential functions of some
family members.
2. Materials and methods
2.1. Sequence analysis
Complementary DNA and genomic sequences were aligned using
the align program [48] and the sip4 program [49]. The nucleotide
sequence databases were searched using the BLAST server at NCBI
[50] in order to identify novel synaptotagmin expressed sequence tag
(EST) sequences.
2.2. RNA analysis
Tissues were dissected from adult or E17 embryo Sprague-Dawley
rats and immediately frozen on dry-ice. Total RNA was prepared
using guanidine isothiocyanate and poly(A) selected using oligo-dT
cellulose. Reverse transcription PCR (RT-PCR) was performed with
Pfu polymerase (Stratagene). Full-length RT-PCR products were
cloned into pBSIIKS3 (Stratagene). RNAse protection assay (RPA)
probes were produced from these clones using the Maxiscript kit
(Ambion) and were hybridised and digested with the Hybspeed
RPA kit (Ambion). RPA products were run on 4% acrylamide se-
quencing gels. Results were collected on a Molecular Dynamics phos-
phorimager. RT-PCR from human adult brain mRNA (Clontech)
employed primers corresponding either to rat synaptotagmin
7 cDNA sequence accession U20106, positions 161^180 and 524^
543, or to human synaptotagmin 5 genomic sequence accession
X96783, positions 392^411 and 4301^4320. RT-PCR products were
digested with PstI (synaptotagmin 7) or PstI and SacI (synaptotagmin
5) and cloned into puc18.
3. Results
We had previously determined the genomic organisation of
the human synaptotagmin 5 gene and described an alternative
splicing event between exons 5 and 6 of its eight exons [51].
Subsequently, RT-PCR analysis of human brain synaptotag-
min 5 mRNA revealed another intriguing alternative splicing
event, exon skipping. Exon 2, which encodes the transmem-
brane sequence, was found to be precisely skipped out of a
signi¢cant proportion of messages. Several di¡erent primer
pairs £anking exon 2 gave equivalent exon-skipped RT-PCR
products. An example is sequence accession Y19236 (see Ta-
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ble 1), which includes exons 1, 3, 4 and 5 but excludes exon 2.
The vast majority of known synaptotagmin gene sequences
are derived from cDNA clones and almost all of the individ-
ual synaptotagmin family members are represented by those
from rat, so we chose to investigate the rat synaptotagmin
family to see whether exon skipping as observed in human
synaptotagmin 5 is a unique event or a more general phenom-
enon.
Although there is no genomic sequence indicating the exon-
intron organisation of the rat synaptotagmin genes, the com-
plete genomic sequence is available for human synaptotagmin
7 (accession AC006409) and partial genomic sequences for
human synaptotagmin 5 (accession X96783) and mouse syn-
aptotagmin 8 (accession U20109). cDNA sequences plotted
against the genomic sequences graphically reveals the intron-
exon structure (Fig. 1). All three genes have a separate trans-
membrane exon and their C2B domain exons are similarly
organised. All of the introns shared between synaptotagmins
5 and 8 have exactly the same location and phase. The C2B
domain intron positions of synaptotagmin 7 also have the
same phase but their location is not precisely equivalent.
The arrangement of the region between the transmembrane
domain and the C2B domain is di¡erent in synaptotagmin 7.
The C2A domain is encoded by only two exons and is pre-
ceeded by two exons which encode the relatively longer linker
sequence between the transmembrane domain and the C2A
domain. RT-PCR-derived sequences of human synaptotagmin
7 brain mRNA together with an examination of the synapto-
tagmin 7 EST sequences at NCBI [50] indicate that at least
another ¢ve novel exons may be included in some synapto-
tagmin 7 mRNAs, as indicated by the arrowhead in Fig. 1.
The RT-PCR sequences (accession numbers Y19237, Y19238,
Y19239 and Y19240) and EST sequences (accession numbers
AI511081, AI713274, AI704933 from rat and R63907, R63992
from human) are described in Table 1. Together, they reveal
¢ve more exons between exons 3 and 4 of the nine exons of
rat synaptotagmin 7 cDNA sequence accession U20106. Fig. 2
Table 1
RT-PCR/EST*
accession
Structure in terms of reference sequence Reference sequence Accession Transmembrane
exon (exon 2)
Y19236 Join: 537^587 (exon 1), 3 424^3 543 (exon 3), 3 672^3 839
(exon 4), 4 207^4 313 (exon 5)
Human synaptotagmin 5
genomic
X96783 1 180^1 352
Y19241 Join: 246^450 (exon 1), 534^640 (exon 3) Rat synaptotagmin 6 cDNA U20105 451^533
Y19242 Join: 161^191 (exon 1), 296^375 (exon 3), 376^500 (exon 4) Rat synaptotagmin 7 cDNA U20106 192^295
Y19242 Join: 48 560^48 590 (exon 1), 77 915^77 994 (exon 3), 96 270^
96 394 (exon 4)
Human synaptotagmin 7
genomic
AC006409 73 171^73 274
Y19237 Join: 86 980^87 167 (exon 3d), 91 124^91 246 (exon 3e),
96 270^96 280 (exon 4)
Human synaptotagmin 7
genomic
AC006409 73 171^73 274
Y19238 Join: 73 241^73 274 (exon 2), 77 915^77 994 (exon 3), 96 270^
96 280 (exon 4)
Human synaptotagmin 7
genomic
AC006409 73 171^73 274
Y19239 Join: 86 980^87 167 (exon 3d), 96 270^96 280 (exon 4) Human synaptotagmin 7
genomic
AC006409 73 171^73 274
Y19240 Join: 73 241^73 274 (exon 2), 77 915^77 994 (exon 3), 82 070^
82 201 (exon 3a), 96 270^96 280 (exon 4)
Human synaptotagmin 7
genomic
AC006409 73 171^73 274
AI511081* Join: 48 509^48 590 (exon 1), 73 171^73 274 (exon 2), 77 915^
77 994 (exon 3), 82 070^82 205 (exon 3a) unknown 19 nt
Human synaptotagmin 7
genomic
AC006409 73 171^73 274
AI713274* Join: poly(T), unknown 38 nt, 83 347^83 123 (exon 3c),
82 843^82719 (exon 3b), 82201^82 140 (exon 3a)
Human synaptotagmin 7
genomic
AC006409 73 171^73 274
AI704933* Join: poly(T), unknown 38 nt, 83 347^83 257 (exon 3c) Human synaptotagmin 7
genomic
AC006409 73 171^73 274
R63907* Join: 48 559^48 590 (exon 1), 73 171^73 274 (exon 2), 77 915^
77 994 (exon 3), 82 070^82 186 (exon 3a)
Human synaptotagmin 7
genomic
AC006409 73 171^73 274
R63992* Join: 96 302^96 270 (exon 4), 83 347^83 288 (exon 3c) Human synaptotagmin 7
genomic
AC006409 73 171^73 274
Fig. 1. cDNA versus genomic sequence plots produced by sip4 [49].
Transmembrane exons are indicated by asterisks. C2A and C2B
exons are indicated. A: Comparison of rat synaptotagmin 5 coding
sequence (accession X84884) and human synaptotagmin 5 genomic
sequence (accession X96783). B: Comparison of mouse synaptotag-
min 8 coding sequence (accession U20107) and mouse genomic syn-
aptotagmin 8 sequence (accession U20109). C: Comparison of rat
synaptotagmin 7 coding sequence (accession U20106) and human
genomic synaptotagmin 7 sequence (accession AC006409). The ar-
rowhead marks the position of novel exons (see Fig. 2 and Table 1).
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Fig. 2. Human chromosome 11 genomic sequence accession AC006409 synaptotagmin 7 gene exon sequences. Nucleotide positions are indicated
at the 5’ and 3’ ends of each exon. The exon phase and translation is indicated for exons 1^9. Translations of the open reading frames of
exons 3a^e are indicated.
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shows all of these exon sequences. The known synaptotagmin
7 translation is shown beneath exons 1^9. The ¢ve novel
exons, 3a^e, are shown with translations of their open reading
frames. This sequence analysis indicates that it is possible that
all synaptotagmin family members have similar exon-intron
arrangements and that alternative splicing including trans-
membrane exon skipping could be widespread.
In order to examine this possibility, RT-PCR and RPA
were performed on all of the N-terminally complete synapto-
tagmins. RT-PCR of rat brain mRNA was used to clone
portions of these synaptotagmins including the transmem-
brane sequence in order to generate suitable probes for
RPA. Two di¡erent overlapping probes were used for each
synaptotagmin gene. Where each of these probes gave a sin-
gle, full-length RPA product, data are shown for only one.
The probe descriptions are listed in Table 2. In every case, the
RT-PCR primers comprise the ¢rst and last 20 nucleotides
(nt). The vast majority of RT-PCR products of synaptotag-
mins 6 and 7 lacked the transmembrane region. However, full-
length sequences matching the accession numbers listed were
Table 2
Panel (Fig. 3) Gene name Accession Nucleotide positions Start codon position Transmembrane amino acid encoding region
A Synaptotagmin 1 X52772 601^1031 526 682^762
B Synaptotagmin 1 X52772 412^841 As for A
C Cyclophilin M19533 35^510 43 N/A
D Synaptotagmin 2 M64488 243^644 115 295^375
E Synaptotagmin 3 D28512 217^550 103 256^333
F Synaptotagmin 6 U20105 411^767 288 447^530 (exon 451^533)
G Synaptotagmin 6 U20105 246^640 As for F
H Synaptotagmin 5 X84884 41^495 75 144^227
I Synaptotagmin 10 U85513 63^520 133 286^363
J Synaptotagmin srg1 U71294 111^440 221 281^340
K Synaptotagmin 11 AF000423 239^719 243 279^362
L Synaptotagmin 4 U14398 268^846 268 307^384
M Synaptotagmin 4 U14398 268^509 As for L
N Synaptotagmin 7 U20106 161^680 161 209^286 (exon 192^295)
O Synaptotagmin 7 U20106 161^500 As for N
Fig. 3. RPA results. Probes A^O are detailed in Table 1. Arrowheads indicate full-length products, the sizes of which are: A 431 nt, B 430 nt,
C 476 nt, D 402 nt, E 334 nt, F 357 nt, G 395 nt, H 455 nt, I 458 nt, J 330 nt, K 481 nt, L 579 nt, M 242 nt, N 520 nt, O 340 nt. Tissue
mRNAs are: 1 adult brain, 2 adult spinal cord, 3 E17 embryo forebrain, 4 adult heart, 5 adult kidney, 6 adult liver, 7 adult lung, 8 adult
spleen, 9 adult testis, 10 adult thymus.
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eventually obtained. The exon-skipped forms of synaptotag-
min 6 (panel G, Table 2), accession Y19241, and of synapto-
tagmin 7 (panel O, Table 2), accession Y19242, are described
in Table 1. Apart from synaptotagmins 6 and 7, all the other
synaptotagmins gave RT-PCR products matching the de-
scribed sequences and were easily cloned as full-length forms.
Rat mRNA from various tissues was analysed by RPA with
32P-labelled probes of similar speci¢c activities (Fig. 3). Cyclo-
philin expression (C) demonstrates that comparable mRNA
levels are present in each lane. Most of the synaptotagmins
are expressed in neural tissue and some are also expressed to a
lesser degree elsewhere (E, N) and some in very low amounts
elsewhere (H, K). A striking ¢nding is that synaptotagmin 6
(F, G) is highly abundant, but in thymus rather than in brain.
Although six of the 10 synaptotagmins examined gave single,
full-length RPA products, four gave multiple products. Syn-
aptotagmin 7 (N, O) gave several products, including full-
length and transmembrane exon-skipped sequences as ex-
pected from RT-PCR, as well as some minor smaller prod-
ucts. Synaptotagmin 6 (F, G) gave three products: full-length
(top), transmembrane exon-skipped (bottom) and a third
form never obtained by RT-PCR. Full-length synaptotagmin
6 RPA products were only found in very small amounts.
Synaptotagmin 1 (A, B) gave di¡erent patterns depending
on the probe used. Synaptotagmin 4 (L, M) gave two RPA
products, the upper of which is the full-length product ex-
pected from RT-PCR analysis. Multiple forms were not ex-
pected for synaptotagmins 1 and 4, as only full-length forms
were ever produced by RT-PCR. The sizes of all the unex-
pected RPA products predict species of mRNA with an un-
known upstream sequence spliced to a downstream region
within or close to the transmembrane region. Synaptotagmins
1, 4, 6 and 7 gave identical RPA products from total RNA
and mRNA (data not shown).
4. Discussion
Four members of the rat synaptotagmin gene family express
alternatively spliced forms di¡ering in their transmembrane
domain regions. In contrast to human synaptotagmin 5, rat
synaptotagmin 5 does not express an exon-skipped form. It is
possible that both the tissue distribution and splicing patterns
of rat and human synaptotagmins are di¡erent. It has been
shown that the rostro-caudal expression pattern of synapto-
tagmin 1 is reversed in rodent and primate [31] and it seems to
be the case that alternative splicing is used to increase func-
tional diversity in higher organisms, particularly in brain [52].
In order to unravel the complexity of synaptotagmin alterna-
tive splicing, it will be necessary to obtain complete genomic
sequences, together with the full repertoire of expressed
mRNAs and panels of isoform-speci¢c antibodies to track
their locations and functions. Genomic sequences are likely
to come soon from human and mouse genome sequencing
projects. Human synaptotagmins 3 and 5 map very close to
each other on chromosome 19 [51], which is currently being
completely sequenced at Lawrence Livermore National Labo-
ratory, USA. Human synaptotagmin 7 is on chromosome 11,
which is being sequenced by several groups. It will be inter-
esting to compare the exon-intron structures of all the synap-
totagmins and to piece together the evolutionary history of
these multidomain proteins. Apart from their C2 domains and
the C-terminal neurexin binding signature [53], the other con-
served regions of the synaptotagmin family lack functional
attributions. Although it has been assumed that synaptotag-
mins would all be integral membrane proteins due to their
transmembrane domains, this work shows that some of
them express forms speci¢cally lacking this domain.
The exon-skipped forms obtained by RT-PCR all result in
frame-shifted messages. It is possible that unknown upstream
exons import novel N-terminal sequences to these exon-
skipped forms. This is suggested by the RPA results with
synaptotagmins 1, 4 and 6, where forms partially matching
the RPA probes could not be obtained by RT-PCR despite
using numerous primer pairs covering their known cDNA
sequences. It is also possible that frame-shifted, exon-skipped
forms may be initiated downstream to produce double C2
domain proteins targeted elsewhere in the cell, although syn-
aptotagmin 4 lacks a suitable downstream methionine.
Published Western blots of synaptotagmins 1, 6 and 7 show
multiple protein forms. The smaller form of synaptotagmin 1
has been assumed to be a proteolytic fragment produced by
digestion at a proteolytically sensitive site immediately C-ter-
minal to the transmembrane domain [54], but it is possible
that it is indeed the product of an alternatively spliced
mRNA. It is interesting to note that a p40 subsequence of
synaptotagmin 1 comprising the cytoplasmic domains has
been found to play a speci¢c role in the secretion of FGF-1
[55^57]. The smaller form of synaptotagmin 6 has been specu-
lated to be a product of alternative splicing [47]. Synaptotag-
min 7 seems to appear in several more forms [24,58]. This is
the ¢rst report of synaptotagmin expression in thymus. Ex-
pression in thymus is very high and may indicate a role in T-
cell functions.
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